Raydiant Oximetry, Inc.

Raydiant Oximetry, Inc. is a groundbreaking company dedicated to the mission of keeping mothers and babies safe during childbirth. Since its foundation in 2016, the U.S.-based firm has been steadfast in its commitment to this noble cause. Raydiant Oximetry is developing a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood, thereby providing obstetricians and patients with crucial information to make informed decisions regarding labor continuation or the need for a cesarean section. The latest milestone for Raydiant Oximetry came with a significant $7.50M Series A investment on 04 June 2024. Notably, the investment was led by a consortium of impactful players, including Global Health Impact Fund, RH Capital, Cross-Border Impact Ventures, VCapital, and March of Dimes. With its focus on biotechnology and healthcare, Raydiant Oximetry is poised to make a substantial contribution to improved maternal and fetal outcomes, reduced cesarean delivery rates, and decreased healthcare costs on a global scale.